Teva Pharmaceutical Industries Limited
TEVA
$36.77
$0.250.69%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.13% | 4.41% | 4.32% | 0.02% | 2.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.13% | 4.41% | 4.32% | 0.02% | 2.07% |
| Cost of Revenue | -1.77% | -1.53% | -1.89% | -0.46% | 1.85% |
| Gross Profit | 10.12% | 10.55% | 10.84% | 0.51% | 2.31% |
| SG&A Expenses | 9.94% | 8.52% | 7.30% | 4.16% | 5.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -385.71% | -312.50% | 90.91% | 5.00% | 27.27% |
| Total Operating Expenses | 6.92% | 1.14% | 1.03% | 1.00% | 2.54% |
| Operating Income | -6.31% | 17.02% | 17.12% | -3.40% | 0.37% |
| Income Before Tax | 1,127.14% | 365.51% | 196.26% | 269.94% | 51.05% |
| Income Tax Expenses | -87.10% | -123.35% | -126.67% | -65.41% | -84.68% |
| Earnings from Continuing Operations | 533.74% | 218.56% | 172.28% | 154.31% | 78.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -120.00% | -102.94% | -102.19% | -80.23% | -98.32% |
| Net Income | 546.84% | 221.62% | 185.97% | 174.24% | 65.12% |
| EBIT | -6.31% | 17.02% | 17.12% | -3.40% | 0.37% |
| EBITDA | -5.64% | 12.37% | 11.79% | -3.55% | -0.96% |
| EPS Basic | 532.73% | 219.76% | 184.91% | 173.52% | 63.80% |
| Normalized Basic EPS | -6.76% | 21.04% | 2.51% | -13.18% | -14.64% |
| EPS Diluted | 467.93% | 215.38% | 182.36% | 169.57% | 60.64% |
| Normalized Diluted EPS | -7.90% | 19.39% | 0.80% | -13.69% | -14.62% |
| Average Basic Shares Outstanding | 1.45% | 1.37% | 1.30% | 1.22% | 1.18% |
| Average Diluted Shares Outstanding | 2.07% | 2.61% | 2.99% | 2.01% | 1.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |